EcoDrugPlus

Toll Like Receptor 9

Ensembl ID : ENSMLUG00000015097
Gene Symbol: TLR9
4 Cross references
82 Possible Orthologues:

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSMLUG00000015003
Gene Symbol: TGFBR1
2 Cross references
230 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSMLUG00000014797
Gene Symbol: TRPA1
2 Cross references
226 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSMLUG00000017423
Gene Symbol: TRPM8
4 Cross references
158 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSMLUG00000016308
Gene Symbol: TRPV1
2 Cross references
134 Possible Orthologues:

Translocator Protein

Ensembl ID : ENSMLUG00000009115
Gene Symbol: TSPO
2 Cross references
126 Possible Orthologues:

Transthyretin

Ensembl ID : ENSMLUG00000003645
Gene Symbol: TTR
2 Cross references
164 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSMLUG00000008011
Gene Symbol: TPH1
2 Cross references
255 Possible Orthologues:

Tubulin Alpha 1a

Ensembl ID : ENSMLUG00000010845
Gene Symbol: TUBA1A
2 Cross references
74 Possible Orthologues:

Tubulin Alpha 1b

Ensembl ID : ENSMLUG00000002622
Gene Symbol: TUBA1B
2 Cross references
190 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSMLUG00000008082
Gene Symbol: TUBA4A
4 Cross references
224 Possible Orthologues:

Tubulin Beta 1 Class Vi

Ensembl ID : ENSMLUG00000014902
Gene Symbol: TUBB1
2 Cross references
186 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).